This solicited report was initially received from an other healthcare  professional, via a Specialty pharmacy, in the 
United States on 31-Dec-2014. follow-up information received from the physician on 03-Feb-2015. A patient, of 
unknown age and gender, was deceased (fatal) while on Ampyra. 
The patient's past medical history was not provided. Concomitant medications were not provided. 
Ampyra (fampridine) was started on an unspecified date for an unknown indication.  Tysabri was co-suspect 
medication was started on an unspecified date "5 years before death" at 300 mg every 4 weeks for MS. 
On an unspecified date, the patient became deceased. The date of death and cause of death were not provided. It 
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 349 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
was unknown if an autopsy was performed. Upon follow-up information received from the physician on 03-Feb-
2015, patients renal function was reported as normal. Physician stated that the patient was deceased due to PML 
due to Tysabri, not related to Ampyra. It was unknown if an autopsy was performed.
The outcome was fatal. 
Ampyra action taken was unknown. Tysabri action taken was unknown.
The reporter (the physician) assessed the relationship between Ampyra and the event as not related.
Follow-up information received from the physician on 03-Feb-2015 provided, co-suspect medication, causality, 
renal function, patient gender and patient date of birth. This information was incorporated into the narrative.